Molecular and clinicopathologic characterization of AML with isolated trisomy 4

American Journal of Clinical Pathology

Volumn 137, Issue 3, 2012, Pages 387-394

  Bains, Ashish ^a   Lu, Gary ^a   Yao, Hui ^a   Luthra, Rajalakshmi ^a   Medeiros, L Jeffrey ^a   Sargent, Rachel L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; AML; KIT; Trisomy 4

Indexed keywords

BIOLOGICAL MARKER; CD135 ANTIGEN; CEBPA PROTEIN; KIT PROTEIN; NUCLEOPHOSMIN; RAS PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER SURVIVAL; CAPILLARY ELECTROPHORESIS; CELL COUNT; CLINICAL ARTICLE; CODON; CYTOGENETICS; EXON; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MALE; METAPHASE CHROMOSOME; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; SURVIVAL RATE; THROMBOCYTE COUNT; TRISOMY; TRISOMY 4; CHROMOSOME 4; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; REMISSION INDUCTION; SURVIVAL RATE; TEXAS; TRISOMY; YOUNG ADULT;

EID: 84859261475     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7ZC9YQERSKGX     Document Type: Article

References (38)

1. Gupta V, Minden MD, Yi QL, et al.Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leuk Res. 2003;27:983-991. (Pubitemid 36814077)
2. Mitelman F, Johansson B, Mertens F, eds. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. 2011. http://cgap.nci.nih.gov/ Chromosomes/Mitelman. Accessed August 2011.
3. Bao L, Wang X, Ryder J, et al.Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol. 2006;77:35-45. (Pubitemid 43876203)
4. Farag SS, Archer KJ, Mrozek K, et al.Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73. (Pubitemid 43996625)
5. United Kingdom Cancer Cytogenetics Group (UKCCG). Primary, single, autosomal trisomies associated with haematological disorders. Leuk Res. 1992;16:841-851.
6. Mecucci C, Van Orshoven A, Tricot G, et al.Trisomy 4 identifies a subset of acute nonlymphocytic leukemias. Blood. 1986;67:1328-1332. (Pubitemid 16080602)
7. Sandberg AA, Morgan R, Sait SN, et al.Trisomy 4: an entity within acute nonlymphocytic leukemia. Cancer Genet Cytogenet. 1987;26:117-125. (Pubitemid 17066686)
8. Ferrari S, Grande A, Zucchini P, et al.Overexpression of c-kit in a leukemic cell population carrying a trisomy 4 and its relationship with the proliferative capacity. Leuk Lymphoma. 1993;9:495-501. (Pubitemid 23209534)
9. Schnittger S, Kohl TM, Haferlach T, et al.KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799. (Pubitemid 43289355)
10. Beghini A, Ripamonti CB, Cairoli R, et al.KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920-925. (Pubitemid 39049899)
11. Spritz RA, Strunk KM, Lee ST, et al.A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics. 1994;22:431-436. (Pubitemid 24258887)
12. Suenaga M, Sanada I, Tsukamoto A, et al.Trisomy 4 in a case of acute myelogenous leukemia accompanied by subcutaneous soft tissue tumors: report of a case and review of the literature. Cancer Genet Cytogenet. 1993;71:71-75. (Pubitemid 24032329)
13. Pedersen B. Trisomy 4: clinical picture, hematology, and survival: presentation of two cases and review of the literature. Hematol Pathol. 1992;6:161-167.
14. Suciu S, Weh HJ, Kuse R, et al.Trisomy 4 in two cases of acute myelomonocytic leukemia. Cancer Genet Cytogenet. 1988;33:19-23.
15. Donti E, Maccari A, Tabilio A, et al.Trisomy 4 in acute nonlymphocytic leukemia: report of two cases and review of the literature. Cancer Genet Cytogenet. 1992;60:195-197.
16. Zollino M, Leone G, Sica S, et al.Trisomy 4 in acute myeloblastic and acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1993;65:115-119. (Pubitemid 23118288)
17. Weber E, Nowotny H, Haas OA, et al.Trisomy 4: a specific karyotype anomaly in primary and secondary acute myeloid leukemia. Leukemia. 1990;4:219-221. (Pubitemid 20099896)
18. Feuring-Buske M, Haase D, Konemann S, et al.Trisomy 4 in "stem cell-like" leukemic cells of a patient with AML. Leukemia. 1995;9:1318-1320.
19. Juneja S, Brown J, Ding JC, et al.Trisomy 4 in acute nonlymphocytic leukemia: an Australian case. Cancer Genet Cytogenet. 1988;34:25-28.
20. Hoyle CF, Boughton BJ, Hayhoe FG. Two further cases of acute myeloid leukemia with trisomy 4. Cancer Genet Cytogenet. 1988;34:29-32.
21. Swerdlow SH, Campo E, Harris NL, et al.eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
22. Gustafson SA, Lin P, Chen SS, et al.Therapy-related acute myeloid leukemia with t(8;21)(q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol. 2009;131:647-655.
23. Shaffer LG, Slovak ML, Campbell LJeds. ISCN: An International System for Human Cytogenetic Nomenclature (2009). Basel, Switzerland: Karger; 2009.
24. Chen W, Jones D, Medeiros LJ, et al.Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 2005;130:726-728. (Pubitemid 43906644)
25. Konoplev S, Huang X, Drabkin HA, et al.Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009;115:4737-4744.
26. Pabst T, Mueller BU, Zhang P, et al.Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27:263-270. (Pubitemid 32201846)
27. Lasa A, Carricondo MT, Carnicer MJ, et al.A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica. 2006;91:1283-1284. (Pubitemid 44408448)
28. Zuo Z, Chen SS, Chandra PK, et al.Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009;22:1023-1031.
29. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al.RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214-1219. (Pubitemid 20318167)
30. Patel KP, Ravandi F, Ma D, et al.Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135:35-45.
31. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Development Core Team; 2009.
32. Thiede C, Steudel C, Mohr B, et al.Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335. (Pubitemid 34627197)
33. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol. 2003;122:523-538. (Pubitemid 36995209)
34. Falini B, Mecucci C, Tiacci E, et al.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266. (Pubitemid 40110814)
35. Schnittger S, Schoch C, Kern W, et al.Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739. (Pubitemid 41739006)
36. Yokota S, Taniwaki M, Okuda T, et al.Acute nonlymphocytic leukemia (M2) with chromosome abnormality trisomy 4 developing eight years after radiation therapy for breast cancer. Blut. 1989;58:27-31. (Pubitemid 19043117)
37. Kao YS, McCormick C, Vial R. Trisomy 4 in a case of acute undifferentiated myeloblastic leukemia with hand-mirror cells. Cancer Genet Cytogenet. 1990;45:265-268. (Pubitemid 20129152)
38. Muss HB, Moloney WC. Chloroma and other myeloblastic tumors. Blood. 1973;42:721-728.